Efficient Blockade of Akt signaling is a determinant factor to overcome resistance to Matuzumab

BACKGROUND: Clinical studies have shown antineoplastic effectiveness of monoclonal antibodies (MAbs) against EGFR for different indications. Several MAbs directed to EGFR were developed recently, such as matuzumab, but there is still lack of information on preclinical data on its combination with ch...

Descripción completa

Detalles Bibliográficos
Autores principales: Meira, Debora D, Almeida, Vitor H, Mororó, Jânio S, Caetano, Mauricio S, Nóbrega, Isabel P, Batista, Delano, Sternberg, Cinthya, Ferreira, Carlos G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3295690/
https://www.ncbi.nlm.nih.gov/pubmed/22185378
http://dx.doi.org/10.1186/1476-4598-10-151

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3295690/
https://www.ncbi.nlm.nih.gov/pubmed/22185378
http://dx.doi.org/10.1186/1476-4598-10-151

Ejemplares similares